Properties (54)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
biotechnology company
|
| gptkbp:acquisition |
Mirati_Therapeutics_acquired_by_another_company
Zymeworks'_product_candidates |
| gptkbp:awards |
industry recognition
|
| gptkbp:CEO |
Charles_M._Baum
|
| gptkbp:clinicalTrials |
Phase 3 trials
combination therapies various cancer treatments Phase 1 trials Phase 2 trials monotherapy studies |
| gptkbp:collaboratesWith |
academic institutions
research organizations |
| gptkbp:communityEngagement |
patient advocacy groups
healthcare_professionals clinical trial participants |
| gptkbp:develops |
targeted therapies
|
| gptkbp:employees |
biotechnology professionals
|
| gptkbp:financials |
publicly traded
|
| gptkbp:focusesOn |
personalized medicine
cancer therapeutics non-small cell lung cancer solid tumors genetic drivers of cancer KRAS_mutations |
| gptkbp:founded |
2010
|
| gptkbp:futurePlans |
global market expansion
investing in technology enhancing research capabilities expanding drug pipeline increasing clinical trials |
| gptkbp:headquarters |
gptkb:San_Diego,_California
|
| https://www.w3.org/2000/01/rdf-schema#label |
Mirati Therapeutics
|
| gptkbp:investmentFocus |
institutional investors
retail investors |
| gptkbp:mission |
transforming the lives of patients
|
| gptkbp:partnerships |
pharmaceutical companies
biopharmaceutical collaborations |
| gptkbp:products |
Adagrasib
MRTX849 Krazati |
| gptkbp:regulatoryCompliance |
EMA_approved_drugs
FDA_approved_drugs |
| gptkbp:researchAndDevelopment |
biomarkers
oncology clinical research drug_discovery |
| gptkbp:stockSymbol |
MRTX
|
| gptkbp:sustainability |
ethical practices
environmental impact reduction corporate responsibility initiatives |
| gptkbp:tradedOn |
gptkb:NASDAQ
|
| gptkbp:tributaryOf |
multiple investigational drugs
|
| gptkbp:vision |
leading in precision medicine
|